Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 601–700 of 1,001
Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Zhang, S., Shen, J., Wang, X., Sun, X., Wu, Y., Zhang, M., Wang, R., & Hu, K. (2023) · View · doi:10.1002/viw.20230010 · Cited by 34
Utilizing gastric cancer organoids to assess tumor biology and personalize medicine
Lin, M., Gao, M., Cavnar, M. J., & Kim, J. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i7.509 · Cited by 37
BTK inhibitors synergise with 5‐FU to treat drug‐resistant TP53‐null colon cancers
Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M. G., Pisano, F., Missaglia, C., Giovannoni, R., Romano, G., McLean, C. M., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5347 · Cited by 32
“Recently, to overcome these limitations in the preclinical validation of novel therapeutic approaches, patient-derived 3D organoids have been developed [41] and shown to recapitulate patient responses in the clinic [42].”
BackgroundVernon, M., Lambert, B., Meryet‐Figuière, M., Brotin, É., Weiswald, L., Paysant, H., Vigneron, N., Wambecke, A., Abeilard, E., Giffard, F., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0510 · Cited by 36
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma
Hansson, K., Radke, K., Aaltonen, K. E., Saarela, J., Mañas, A., Sjölund, J., Smith, E. M. K., Pietras, K., Påhlman, S., Wennerberg, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4434 · Cited by 34
“Recently, gastrointestinal cancer 3D patient–derived organoids were shown to effectively recapitulate clinical responses (8).”
BackgroundUse of preclinical models for malignant pleural mesothelioma
Shamseddin, M., Obacz, J., Garnett, M. J., Rintoul, R. C., Francies, H. E., & Marciniak, S. J. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-216602 · Cited by 32
Volumetric growth tracking of patient-derived cancer organoids using optical coherence tomography
Gil, D. A., Deming, D. A., & Skala, M. C. (2021) · Biomedical Optics Express · doi:10.1364/boe.428197 · Cited by 33
Automation of Organoid Cultures: Current Protocols and Applications
Louey, A., Hernández, D., Pébay, A., & Daniszewski, M. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211024547 · Cited by 40
Intestinal multicellular organoids to study colorectal cancer
Idris, M., Alves, M. M., Hofstra, R. M. W., Mahé, M. M., & Melotte, V. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188586 · Cited by 37
Challenges for the Applications of Human Pluripotent Stem Cell-Derived Liver Organoids
Chang, M., Bogacheva, M. S., & Lou, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748576 · Cited by 37
In-Depth Comparison of Matrigel Dissolving Methods on Proteomic Profiling of Organoids
Wang, M., Yu, H., Zhang, T., Cao, L., Du, Y., Xie, Y., Ji, J., & Wu, J. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100181 · Cited by 37
“CR solution (also named “Matrisperse” previously) (2, 13–15), enzymatic digestion using dispase (3, 16–18), and chemical method involving PBS–EDTA (PE) buffer are widely used (8, 9, 19).”
MethodThe gut microbiota can orchestrate the signaling pathways in colorectal cancer
Bennedsen, A. L. B., Furbo, S., Bjarnsholt, T., Raskov, H., Gögenür, I., & Kvich, L. (2022) · Apmis · doi:10.1111/apm.13206 · Cited by 34
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Williams, S. T., Wells, G., Conroy, S., Gagg, H., Allen, R. J., Rominiyi, O., Helleday, T., Hullock, K., Pennington, C. E. W., Rantala, J., et al. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.32 · Cited by 37
Advanced models for respiratory disease and drug studies
Shrestha, J., Paudel, K. R., Nazari, H., Dharwal, V., Bazaz, S. R., Johansen, M. D., Dua, K., Hansbro, P. M., & Warkiani, M. E. (2023) · Medicinal Research Reviews · doi:10.1002/med.21956 · Cited by 34
Stem Cells and Organoids: A Paradigm Shift in Preclinical Models Toward Personalized Medicine
Luce, E., & Duclos‐Vallée, J. (2025) · Pharmaceuticals · doi:10.3390/ph18070992 · Cited by 35
“These systems retain patient-specific genetic, epigenetic, and phenotypic features, enabling individualized approaches to treatment selection and drug development [7,63].”
InfluentialFranco, G. D., Usai, A., Funel, N., Palmeri, M., Montesanti, I. E. R., Bianchini, M., Gianardi, D., Furbetta, N., Guadagni, S., Vasile, E., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2792 · Cited by 31
The Progress and Clinical Application of Breast Cancer Organoids
Yu, J. S., & Huang, W. (2020) · International Journal of Stem Cells · doi:10.15283/ijsc20082 · Cited by 34
“Several studies reported the assessed sensitivity up to 100%, the specificity of 93%, and the positive rate of 88% (31).”
BackgroundLiu, C., Niu, K., & Xiao, Q. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa313 · Cited by 33
Current and Future Perspectives of the Use of Organoids in Radiobiology
Nagle, P. W., & Coppes, R. P. (2020) · Cells · doi:10.3390/cells9122649 · Cited by 35
“Moreover, the study successfully identified differential inter- and intra-patient responses to common chemotherapeutic agents for gastrointestinal cancer treatment [104].”
BackgroundResultInfluentialPPARγ induces PD-L1 expression in MSS+ colorectal cancer cells
Gutting, T., Hauber, V., Pahl, J. H. W., Klapproth, K., Wu, W., Dobrota, I., Herweck, F., Reichling, J., Helm, L., Schroeder, T., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1906500 · Cited by 33
Svanström, A., Rosendahl, J., Salerno, S., Leiva, M. C., Gregersson, P., Berglin, M., Bogestål, Y. R., Lausmaa, J., Oko, A., Chinga‐Carrasco, G., et al. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac0451 · Cited by 40
Tumor models to assess immune response and tumor-microbiome interactions in colorectal cancer
Yuan, C., Zhao, X., Wangmo, D., Alshareef, D., Gates, T. J., & Subramanian, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107981 · Cited by 34
“Patient-derived organoids also are promising preclinical models that can predict clinical outcomes by recapitulating patient responses in the clinic (Vlachogiannis et al., 2018).”
BackgroundFlood, M. P., Narasimhan, V., Wilson, K., Lim, W. M., Ramsay, R. G., Michael, M., & Heriot, A. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10829-x · Cited by 36
High-resolution positron emission microscopy of patient-derived tumor organoids
Khan, S., Shin, J. H., Ferri, V., Cheng, N., Noel, J. E., Kuo, C. J., Sunwoo, J. B., & Pratx, G. (2021) · Nature Communications · doi:10.1038/s41467-021-26081-6 · Cited by 33
Wu, Y., Li, K., Li, Y., Sun, T., Liu, C., Dong, C., Zhao, T., Tang, D., Chen, X., Chen, X., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1201 · Cited by 32
Angelis, M. L. D., Francescangeli, F., Nicolazzo, C., Xhelili, E., Torre, F. L., Colace, L., Bruselles, A., Macchia, D., Vitale, S., Gazzaniga, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869485 · Cited by 34
“Patient-derived organoids (PDOs) obtained by subcutaneous transplantation of tumor fragments have been shown to reproduce the architectural and histological features of the original tumor tissue, and can be effectively used for the characterization/validation of molecular vulnerabilities for therapeutic purposes (37,…”
BackgroundKinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises
Skorda, A., Bay, M. L., Hautaniemi, S., Lahtinen, A., & Kallunki, T. (2022) · Cancers · doi:10.3390/cancers14246257 · Cited by 35
“The patient-derived ex vivo tumor organoid cultures (PDOs) can recapitulate the genetic, histological, and molecular heterogeneity of the primary tumor, thus being an ideal model system for personalized ex vivo testing of drug sensitivity and resistance [74,124].”
BackgroundPatient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients
Khorsandi, D., Yang, J., Foster, S., Khosravi, S., Kouchehbaghi, N. H., Zarei, F., Lee, Y. B., Runa, F., Gangrade, A., Voskanian, L., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302331 · Cited by 34
Grand challenges in organoid and organ-on-a-chip technologies
Skardal, A. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1366280 · Cited by 37
Perspective on quantitative phase imaging to improve precision cancer medicine
Liu, Y., & Uttam, S. (2024) · Journal of Biomedical Optics · doi:10.1117/1.jbo.29.s2.s22705 · Cited by 41
“106 – 108 QPI has established its utility in assessing the physical properties of 2D cell lines, such as in studying mass dynamics in response to drug treatments, as previously discussed.”
BackgroundLiu, S., Chen, J.-H., Li, L., Ye, Z., Liu, J., Chen, Y., Hu, B., Tang, J.-H., Feng, G., Li, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202412593 · Cited by 48
Li, P., Huang, M., Ma, Y., Zhang, Y., & Shi, C. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03628-3 · Cited by 42
Mallya, D., Gadre, M. A., Varadharajan, S., & Vasanthan, K. S. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1457872 · Cited by 38
Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays
Yakavets, I., Kheiri, S., Cruickshank, J., Hickman, R. J., Rakhshani, F., Aldeghi, M., Rajaonson, E. M., Young, E. W. K., Aspuru‐Guzik, A., Cescon, D. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt1851 · Cited by 35
Choudhary, S., Dubey, A., Singh, A., Zamboni, P., Gupta, N., Singh, R., Tisato, V., Aggarwal, L. M., & Gemmati, D. (2025) · Exploration of BioMat-X · doi:10.37349/ebmx.2025.101351 · Cited by 32
Bolck, H. A., Pauli, C., Göbel, E., Mühlbauer, K., Dettwiler, S., Moch, H., & Schraml, P. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00246 · Cited by 29
“PDC models are characterized by increasing complexity and biological relevance as they retain patient-specific features and are amenable to a variety of experimental applications (Pauli et al., 2017; Drost and Clevers, 2018; Vlachogiannis et al., 2018; Bolck et al., 2019).”
BackgroundKawai, S., Yamazaki, M., Shibuya, K., Yamazaki, M., Fujii, E., Nakano, K., & Suzuki, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60145-9 · Cited by 32
Microfluidic droplets as structural templates for Matrigel to enable 1-week large organoid modeling
Zhang, W., Li, D., Jiang, S., Galan, E. A., Zhang, Z., Huang, L., & Ma, S. (2021) · Chemical Engineering Science · doi:10.1016/j.ces.2021.116632 · Cited by 35
Lee, J. H., Kim, H., Lee, S. H., Ku, J., Chun, J. W., Seo, H., Kim, S., Paik, W. H., Ryu, J. K., Lee, S. K., et al. (2021) · Gut and Liver · doi:10.5009/gnl210166 · Cited by 37
Zheng, Q., Zhang, B., Li, C., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.850732 · Cited by 35
“In addition, organoids may help identify new biomarkers for predicting treatment response through matching molecular profiling of tumor organoids to drug screening results (56).”
BackgroundZhao, S., Wu, X., Tan, Z., Ren, Y., Li, L., Ou, J., Lin, Y., Song, H., Feng, L., Seto, D., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00209-23 · Cited by 32
“The 3D organoid culture technologies have been widely used in different stages of drug discovery, including diseases modeling (54), target identification and validation (55), screening (56), target selection (57), and toxicity assessment (58), as well as representing potential tools for predicting therapeutic response…”
BackgroundIntegration of Sensors in Gastrointestinal Organoid Culture for Biological Analysis
Kim, G.-A., Ginga, N. J., & Takayama, S. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.03.002 · Cited by 35
“human studies, a simplified, human-relevant, GI model system would significantly accelerate mechanistic understanding, GI-focused drug development, and precision medicine efforts.(5) Fortunately, GI organoids recently have been developed that preserve key human cell physiology while allowing easier manipulation.”
Background3D gastrointestinal models and organoids to study metabolism in human colon cancer
Silva‐Almeida, C., Ewart, M., & Wilde, C. J. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.019 · Cited by 33
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
VIBRANT: spectral profiling for single-cell drug responses
Liu, X., Shi, L., Zhao, Z., Shu, J., & Min, W. (2024) · Nature Methods · doi:10.1038/s41592-024-02185-x · Cited by 32
“In precision medicine, VIBRANT can evaluate patient-derived organoids, which emerged as robust preclinical models 48 , with photothermal MIR imaging 46 or advanced Raman microscopy enabling volumetric imaging.”
Toward reproducible tumor organoid culture: focusing on primary liver cancer
Guo, L., Li, C., & Gong, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1290504 · Cited by 38
Parente, I. A., Chiara, L., & Bertoni, S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122875 · Cited by 36
Merrill, N. M., Kaffenberger, S. D., Bao, L., Vandecan, N. M., Goo, L., Apfel, A. M., Cheng, X., Qin, Z., Liu, C.-J., Bankhead, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.05.026 · Cited by 39
Kan, L., Yu, Y., Wang, Y., Shi, L., Fan, T., Chen, H., & Ren, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02328-4 · Cited by 33
“…in vitro, orthotopic xenograft models in mice and patient outcomes in clinical trials, researchers have demonstrated a sensitivity of 100%, specificity of 93%, positive predictive value of 88%, and negative predictive value of 100% for predicting responses to targeted and chemotherapy drugs [240].”
Clinical Implementation of Precision Medicine in Gastric Cancer
Jeon, J., & Cheong, J. (2019) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2019.19.e25 · Cited by 31
“, the clinical trials conducted on both patients and models derived from them—can further accelerate drug development [62,73,86,87] by facilitating molecular, cellular, and clinical analyses to validate clinical outcome data and investigating the response and resistance to therapeutics.”
BackgroundCurrent methods in translational cancer research
Lee, M. W., Miljanic, M., Triplett, T., Ramírez, C., Aung, K. L., Eckhardt, S., & Capasso, A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09931-5 · Cited by 33
Engineered models of tumor metastasis with immune cell contributions
Graney, P. L., Tavakol, D. N., Chramiec, A. G., Ronaldson-Bouchard, K., & Vunjak‐Novakovic, G. (2021) · iScience · doi:10.1016/j.isci.2021.102179 · Cited by 32
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 34
Metabolic Studies in Organoids: Current Applications, Opportunities and Challenges
Richiardone, E., den Bossche, V. V., & Corbet, C. (2022) · Organoids · doi:10.3390/organoids1010008 · Cited by 32
“Major recent advances in 3D culture technology have led to the development of patient-derived tumor organoids (PDTO) for a variety of cancer types, including breast [107], bladder [108], colorectal [109], head and neck [110], liver [111], pancreatic [112], gastrointestinal [113], glioblastoma [114], retinoblastoma [11…”
BackgroundLv, T., Shen, L., Xu, X., Yao, Y., Mu, P., Zhang, H., Wan, J., Wang, Y., Guan, R., Li, X., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34302 · Cited by 33
“Patient-derived tumor organoids (PDTOs) are three-dimensional preclinical models that can mimic genomic alterations, morphological features, biological characteristics, and the clinical responses to treatment of the original tumor.(27-30) The study of Ooft reported that PDTOs can predict response to irinotecan with or…”
BackgroundBiomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
iPSC-Derived Enterocyte-like Cells for Drug Absorption and Metabolism Studies
Macedo, M. H., Araújo, F., Martínez, E., Barrias, C. C., & Sarmento, B. F. C. C. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.001 · Cited by 31
Zou, J., Wang, S., Chai, N., Yue, H., Ye, P., Guo, P., Li, F., Wei, B., Ma, G., Wei, W., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01431-8 · Cited by 30
“Genomic characterizations of GC PDOs In addition to histopathological characterization of organoids, previous studies have also revealed that organoids can recapitulate the genomic profiles of their corresponding tumors [24, 25].”
BackgroundProtocol for ex vivo culture of patient-derived tumor fragments
Roelofsen, L. M., Voabil, P., de Bruijn, M. J. W., Herzig, P., Zippelius, A., Schumacher, T. N., & Thommen, D. S. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102282 · Cited by 36
MASTRONIKOLIS, N. S., Delides, A., Kyrodimos, E., Piperigkou, Z., Spyropoulou, D., Giotakis, E. I., Tsiambas, E., & Karamanos, N. K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09476-8 · Cited by 36
Kalla, J., Pfneissl, J., Mair, T., Tran, L., & Egger, G. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00960-8 · Cited by 33
Tardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 34
“Vlachogiannis et al. [183] prepared a biobank of metastatic gastrointestinal cancers with a 70% establishment success.”
BackgroundSuvilesh, K. N., Manjunath, Y., Nussbaum, Y. I., Gadelkarim, M., Raju, M., Srivastava, A., Li, G., Warren, W. C., Shyu, C., Gao, F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3980 · Cited by 36
“The drug responses observed in PDTOs also match the ones observed in patients with cancer and PDX models in vivo (7, 8).”
Yang, J., Zhang, X., Liu, Z., Yang, C., Li, S., Zhou, H., & Gao, Z. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155882 · Cited by 30
Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives
Qiao, D., Wang, R. C., & Wang, Z. (2025) · Cells · doi:10.3390/cells14221804 · Cited by 45
Label-free redox imaging of patient-derived organoids using selective plane illumination microscopy
Favreau, P. F., He, J., Gil, D. A., Deming, D. A., Huisken, J., & Skala, M. C. (2020) · Biomedical Optics Express · doi:10.1364/boe.389164 · Cited by 31
Nitika, N., Blackman, J. S., Knighton, L. E., Takakuwa, J. E., Calderwood, S. K., & Truman, A. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-70764-x · Cited by 28
“personalized medicine efforts and influence clinical decisions [45, 46].”
BackgroundRecycling the Purpose of Old Drugs to Treat Ovarian Cancer
Nunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207768 · Cited by 34
Primate Organoids and Gene-Editing Technologies toward Next-Generation Biomedical Research
Chen, C., Ji, W., & Niu, Y. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.03.010 · Cited by 28
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 35
“The organoid culture system is a powerful tool for personalized medicine and is used in co-clinical trials because the response of PDOs to drugs largely mimics the initial response of corresponding patients to the same drugs (24, 108, 111, 117, 118) (Figure 2).”
MethodColorectal Cancer Stem Cells: An Overview of Evolving Methods and Concepts
Angelis, M. L. D., Francescangeli, F., Zeuner, A., & Baiocchi, M. (2021) · Cancers · doi:10.3390/cancers13235910 · Cited by 33
“Importantly, patient-derived organoids have allowed generating of biobanks that have proved highly representative of gastrointestinal cancer patients’ response to drugs and radiation [10,11,57,58].”
BackgroundEk, F., Blom, K., Selvin, T., Rudfeldt, J., Andersson, C. R., Senkowski, W., Bréchot, C., Nygren, P., Larsson, R. L., Jarvius, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12519-4 · Cited by 28
Pancreatic cancer circulating tumor cells: applications for personalized oncology
DiPardo, B. J., Winograd, P., Court, C. M., & Tomlinson, J. S. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1511429 · Cited by 28
Deciphering Organoids: High-Dimensional Analysis of Biomimetic Cultures
Qin, X., & Tape, C. J. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.10.013 · Cited by 28
Plattner, C., Lamberti, G., Blattmann, P., Kirchmair, A., Rieder, D., Loncova, Z., Sturm, G., Scheidl, S., Ijsselsteijn, M., Fotakis, G., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108399 · Cited by 27
“However, despite earlier encouraging reports [8,9], conflicting results have been reported 84 regarding the capability of PDOs to predict tumor responses to specific drugs [10] Moreover, a recent 85 study showed that despite sensitivity of the PDOs to selected kinase inhibitors, CRC patients from 86 which these cells…”
ResultHuang, L., Xu, Y., Wang, N., Yi, K., Xi, X., Si, H., Zhang, Q., Xiang, M., Rong, Y., Yuan, Y., et al. (2023) · Small Methods · doi:10.1002/smtd.202301009 · Cited by 31
Patient-derived organoids: a promising tool for breast cancer research
Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., & Liu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1350935 · Cited by 32
Ma, W., Zheng, Y., Yang, G.-Z., Zhang, H., Lu, M., Ma, H., Wu, C., & Lu, H. (2024) · Materials Horizons · doi:10.1039/d4mh00228h · Cited by 30
Precision oncology: current and future platforms for treatment selection
Tang, X., Berger, M. F., & Solit, D. B. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.009 · Cited by 35
Tumor organoids in immunotherapy: from disease modeling to translational research
Si, Q., Tao, S., Wu, J., Ma, J., Li, Z. Y., Feng, X., Song, J., Kong, T., & Zhou, Z. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011733 · Cited by 32
“103 By creating treatment-sensitive and resistant organoids, researchers can explore resistance mechanisms and test personalized strategies.”
Enomoto, M., Takemoto, D., & Igaki, T. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.07.002 · Cited by 30
Tumor organoids for cancer research and personalized medicine
Yang, H., Wang, Y., Wang, P., Zhang, N., & Wang, P. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0335 · Cited by 42
Application of Organoid Models in Prostate Cancer Research
Zhou, L., Zhang, C., Zhang, Y., & Shi, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736431 · Cited by 31
“Several studies have demonstrated that drug response to organoids may predict clinical outcomes (76, 77).”
BackgroundEstablishment of gastric signet ring cell carcinoma organoid for the therapeutic drug testing
Li, G., Ma, S., Wu, Q., Kong, D., Yang, Z., Gu, Z., Feng, L., Zhang, K., Cheng, S., Tian, Y., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00803-7 · Cited by 30
“Previous studies have reported the use of GC organoids to test drug responses [19, 21, 22].”
Low Colorectal Tumor Removal by E-Cadherin Destruction-Enabled Tumor Cell Dissociation
Li, M., Bao, Q., Guo, J., Xie, R., Shen, C., Wei, Q., Hu, P., Qin, H., & Shi, J. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c04797 · Cited by 26
The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
“Multiple studies have shown that a preclinical model PDCO has the potential to predict patient drug response in highthroughput screening systems [50,51,58,60,64,65].”
BackgroundPerréard, M., Florent, R., Divoux, J., Grellard, J., Lequesne, J., Briand, M., Clarisse, B., Rousseau, N., Lebreton, E., Dubois, B., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10692-x · Cited by 27
“A pilot study showed that PDTO from metastatic gastrointestinal tumors predicted the response of 21 patients to different chemotherapies (100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value) [13].”
BackgroundOrganoid: Bridging the gap between basic research and clinical practice
Weng, G., Tao, J., Liu, Y., Qiu, J., Su, D., Wang, R., Luo, W., & Zhang, T. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216353 · Cited by 30
Hallmark discoveries in the biology of Wilms tumour
Perotti, D., Williams, R. D., Wegert, J., Brzezinski, J. J., Maschietto, M. C., Ciceri, S., Gisselsson, D., Gadd, S., Walz, A. L., Furtwängler, R., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00824-0 · Cited by 35
“Results of several studies have demonstrated that patient-derived tumour organoids recapitulate patient drug responses 224–227 , suggesting that organoids can be used for the development of individualized therapies.”
CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids
Hennig, A., Wolf, L., Jahnke, B., Polster, H., Seidlitz, T., Werner, K., Aust, D. E., Hampe, J., Distler, M., Weitz, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/1024614 · Cited by 33
“These patientderived cancer organoids open up new opportunities for personalized therapy, as they mimic in vitro to a high-degree response of the tumor in vivo [14].”
BackgroundFirst-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Abbott, J. M., Zhou, Q., Esquer, H., Pike, L. A., Broneske, T. P., Rinaldetti, S. L., Abraham, A. D., Ramirez, D. A., Lunghofer, P. J., Pitts, T. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0106 · Cited by 30
“Briefly, cells were seeded at 5,000 cells per well in 96-well plates and cultured by established methods (30) allowing PDTO formation over 72 hours.”
MethodLi, H., Feng, H., Zhang, T., Wu, J., Shen, X., Xu, S., Xu, L., Wang, S., Zhang, Y., Jia, W., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01971-7 · Cited by 29
“Currently, to enhance the predictability of drug clinical efficacy, complex preclinical models are being employed [46, 47].”
BackgroundPancreatic Progenitors and Organoids as a Prerequisite to Model Pancreatic Diseases and Cancer
Hohwieler, M., Müller, M., Frappart, P., & Heller, S. (2019) · Stem Cells International · doi:10.1155/2019/9301382 · Cited by 32
“Currently, the value of hTOs in predicting a patient-specific response for a distinct therapeutic regime remains to be determined; however, current work on other gastrointestinal cancer types is promising [85].”
BackgroundEmerging trends in modeling human liver disease in vitro
Underhill, G. H., & Khetani, S. R. (2019) · APL Bioengineering · doi:10.1063/1.5119090 · Cited by 30
Yu, Y., Zhu, Y.-J., Xiao, Z., Chen, Y., Chang, X., Liu, Y., Tang, Q., & Zhang, H. (2022) · Biomarker Research · doi:10.1186/s40364-022-00421-0 · Cited by 29
“In current cohorts of patients, the response of GIC PDOs to anti-cancer therapies resembles the response of the patients in clinic [10, 34, 53].”
BackgroundMethodResultInfluentialGhorbaninejad, M., Asadzadeh‐Aghdaei, H., Baharvand, H., & Meyfour, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121506 · Cited by 31
Organotypic Models for Functional Drug Testing of Human Cancers
Huang, Y. L., Dickerson, L. K., Kenerson, H. L., Jiang, X., Pillarisetty, V. G., Tian, Q., Hood, L., Gujral, T. S., & Yeung, R. S. W. (2023) · BME Frontiers · doi:10.34133/bmef.0022 · Cited by 29
“In metastatic gastrointestinal cancers, it has been shown that PDO models had a positive predictive value of 88% in response to targeted agents or chemotherapy compared to patients in clinical trials [33].”
ResultCutoff value of IC50 for drug sensitivity in patient-derived tumor organoids in colorectal cancer
Tang, Y., Wang, T., Hu, Y., Ji, H., Yan, B., Hu, X., Zeng, Y., Hao, Y., Xue, W., Chen, Z., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107116 · Cited by 28
“Nevertheless, the small number of patients analyzed as well as the lack of validated clinical responses, were insufficient to confirm the accuracy of using PDTOs to predict efficacy.(18) More importantly, the specific half-maximal inhibitory concentration (IC50) cutoff value for determining drug sensitivity or drug re…”
ResultAnimal Models of Human Disease
Green, S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009025836 · Cited by 31
How to find the right drug for each patient? Advances and challenges in pharmacogenomics
Kalamara, A., Tobalina, L., & Sáez-Rodríguez, J. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.07.001 · Cited by 28
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.